Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1324916
                    [Title] => Preventing pneumonia in the elderly
                    [Summary] => 
Results of a landmark clinical trial evaluating the efficacy of Pfizer’s pneumococcal vaccine confirm that it can prevent community-acquired pneumonia in adults aged 65 and above.

                    [DatePublished] => 2014-05-20 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

COMMUNITY-ACQUIRED PNEUMONIA IMMUNIZATION TRIAL

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1324916
                    [Title] => Preventing pneumonia in the elderly
                    [Summary] => 
Results of a landmark clinical trial evaluating the efficacy of Pfizer’s pneumococcal vaccine confirm that it can prevent community-acquired pneumonia in adults aged 65 and above.

                    [DatePublished] => 2014-05-20 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

Preventing pneumonia in the elderly

May 20, 2014 - 12:00am

Results of a landmark clinical trial evaluating the efficacy of Pfizer’s pneumococcal vaccine confirm that it can prevent community-acquired pneumonia in adults aged 65 and above.

Health And Family